Celsion Co. (NASDAQ:CLSN) – Equities research analysts at Oppenheimer cut their FY2022 EPS estimates for shares of Celsion in a report released on Thursday, August 15th. Oppenheimer analyst H. Singh now forecasts that the biotechnology company will post earnings of $1.65 per share for the year, down from their previous estimate of $1.76. Oppenheimer also issued estimates for Celsion’s FY2023 earnings at $3.33 EPS.
A number of other equities research analysts have also weighed in on CLSN. Zacks Investment Research raised shares of Celsion from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Tuesday. Brookline Capital Management reissued a “buy” rating on shares of Celsion in a report on Thursday, July 25th. Finally, ValuEngine raised shares of Celsion from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
Celsion (NASDAQ:CLSN) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 1,489.20% and a negative return on equity of 53.40%.
An institutional investor recently raised its position in Celsion stock. Vanguard Group Inc. grew its stake in shares of Celsion Co. (NASDAQ:CLSN) by 43.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 704,651 shares of the biotechnology company’s stock after acquiring an additional 211,779 shares during the period. Vanguard Group Inc. owned about 3.44% of Celsion worth $1,282,000 at the end of the most recent quarter. 4.73% of the stock is currently owned by institutional investors and hedge funds.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Recommended Story: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.